Vancouver biotech NanoVation Therapeutics has announced a multi-year partnership with Novo Nordisk to advance the development of novel genetic medicines targeting cardiometabolic and rare diseases.
With the partnership, NanoVation will receive research funding and is eligible to receive up to approximately USD $600 million in up-front cash and potential milestone payments, as well as tiered royalties on future product sales as part of a multi-year deal
The partnership combines NanoVation Therapeutics’ proprietary long-circulating lipid nanoparticle (lcLNP™) technology for RNA delivery to cells outside of the liver with Novo Nordisk’s expertise in cardiometabolic and rare disease R&D and clinical translation.
NanoVation was co-founded by Pieter Cullis, PhD (pictured), current Board Chair, who is widely regarded as the founding father of LNP technology.
“Genetic medicine is at a pivotal moment and this partnership marks a major milestone for NanoVation as an innovator in nucleic acid delivery,” said Cullis.
“By combining NanoVation’s expertise in extrahepatic delivery with Novo Nordisk’s expertise in cardiometabolic and rare diseases we have the potential to create truly transformative therapies.”
Leave a Reply